[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, Semagacestat did not show effectiveness for Alzheimer's Disease. In a phase 3 trial, Semagacestat did not improve cognitive status and patients receiving the higher dose had significant worsening of functional ability. Additionally, patients treated with Semagacestat experienced more adverse events, including skin cancers and infections. The trial was terminated before completion due to the recommendation of the data and safety monitoring board. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]